Plain-English translation of NCT07020533 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CMV-MVA Triplex Vaccine, a new vaccine designed to boost your immune system's ability to fight cytomegalovirus (CMV)—a common virus that can become dangerous after stem cell transplant. The vaccine is given to both your stem cell donor and to you after transplant. This treatment aims to prevent CMV from becoming active and causing serious illness, so you may need less intensive monitoring and fewer additional medications afterward.
After stem cell transplant, CMV can reactivate and cause life-threatening complications. Currently, patients need frequent blood tests and preventive medications to catch and treat CMV early. This trial is testing whether the new treatment can strengthen your immune system enough to prevent CMV from becoming a problem in the first place, which could reduce your need for extra drugs and constant monitoring.
You likely qualify if…
You likely don't qualify if…
If you are a recipient, you will receive chemotherapy to prepare your body, then a stem cell transplant on day 0. You will receive the vaccine three times (on days 28, 56, and 100 after transplant) as a shot, and you will take a medication called by mouth or IV from day 7 to day 100. Throughout the study, you will have regular blood draws to monitor your immune response and check for any virus. Your stem cell donor will receive one vaccine shot and undergo a procedure to collect stem cells, plus some blood tests.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States